Research Article Open Access

Highlight of New Phosphodiesterase 10A Inhibitors Using Molecular Docking

Halla Belhoula1, El Hassen Mokrani1, Abderrahmane Bensegueni1 and Djihane Bioud1
  • 1 University Brother Mentouri Constantine 1, United States


Phosphodiesterase 10A (PDE 10A) is an effective therapeutic approach for treatments of Schizophrenia (SCZ). In order to identify in silico new potent PDE 10A inhibitors, molecular docking approach was used. In this context, the compound S235 was predicted to exhibit a high potential PDE 10A inhibitory activity among 369 compounds tested. The predicted binding energy of this compound was improved from -10.28 to -13.80 Kcal/mol by structural replacements of its chemical grouping. Finally, the proposed compound was predicted to have good ADMET properties.

Current Research in Bioinformatics
Volume 8 No. 1, 2019, 34-37


Submitted On: 25 December 2019 Published On: 27 February 2020

How to Cite: Belhoula, H., Mokrani, E. H., Bensegueni, A. & Bioud, D. (2019). Highlight of New Phosphodiesterase 10A Inhibitors Using Molecular Docking. Current Research in Bioinformatics, 8(1), 34-37.

  • 1 Citations



  • Molecular Docking
  • AutoDock
  • Phosphodiesterase 10A
  • Binding Energy
  • Schizophrenia